
Semaglutide Vision Loss: What the Research Says About NAION Risk
Updated: Nov 11
Written and medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 17, 2026
Quick Answer
Semaglutide vision loss refers to NAION, a rare eye condition reported in some people taking semaglutide. Observational studies link the drug to a higher risk, mainly in people with type 2 diabetes, but it may affect up to 1 in 10,000 users. Randomized trials have not confirmed a clear increase, and no study has proven the drug causes it.
Semaglutide vision loss is back in the headlines. On October 10, 2026, NPR reported on lawsuits from people who say they lost sight from a rare eye condition called NAION while taking semaglutide (sold under brand names including Ozempic and Wegovy) or similar GLP-1 medicines [1]. Here is the short answer: large observational studies link semaglutide to a higher relative risk of NAION, mainly in people with type 2 diabetes, but the condition remains very rare. European regulators estimate it may affect up to 1 in 10,000 people taking semaglutide [2]. Randomized trials have not confirmed a clear increase, and no study has proven that the drug causes it [6][7][14].

What the research says
Pooled studies link semaglutide to about double the risk of NAION in type 2 diabetes, but the absolute risk is very low. A 2026 review of observational studies found a hazard ratio of 2.17 for NAION in semaglutide users with type 2 diabetes compared with other glucose-lowering drugs. The absolute risk was 0.014%, or roughly 1 extra case per 7,000 people treated each year. (Chrzanowski et al., PLoS Medicine, 2026)
Randomized trials have not shown a clear increase. Across 20 randomized trials with 83,288 participants followed for about 3 years, GLP-1 medicines were not linked to a significant rise in ischemic optic neuropathy (odds ratio 1.50, 95% CI 0.49–4.63) or in vision loss events. (Li et al., Diabetes Care, 2026)
The signal is strongest in diabetes, not weight loss. In people with diabetes, observational data showed 26.7 NAION cases per 100,000 person-years on semaglutide versus 18.9 without it (hazard ratio 1.85). For weight loss, there was no clear evidence of increased risk (hazard ratio 1.57, 95% CI 0.69–3.59). (Liu et al., Ophthalmology, 2026)
Key takeaways
NAION is a sudden, usually painless loss of vision in one eye caused by poor blood flow to the optic nerve. The vision loss is generally permanent [1][3].
Observational studies link semaglutide to roughly twice the relative risk of NAION, mostly in people with type 2 diabetes [2][5].
In absolute terms, the risk is very rare: up to about 1 in 10,000 users, according to the European Medicines Agency [2].
Pooled randomized trials have not confirmed a clear increase [6].
Do not stop your medicine on your own. Seek urgent medical care for any sudden loss of vision [2][3].
What is NAION, and how is it tied to semaglutide vision loss?
NAION stands for nonarteritic anterior ischemic optic neuropathy. In plain terms, it is caused by tiny strokes that cut off blood flow to the optic nerve [1]. The World Health Organization describes it as a leading cause of vision loss in adults and the second most common optic nerve disease after glaucoma. It typically causes sudden, painless vision loss in one eye, the loss is generally irreversible, and there is no proven treatment [3].
Many NAION risk factors overlap with the people who are prescribed semaglutide. Diabetes itself raises the risk, and so do low blood pressure overnight and a very small optic nerve cup [14]. A 2025 review notes that this anatomical "disc at risk" is easily detected during an eye exam [12].
The first warning sign came in 2024. A study of 16,827 patients seen by neuro-ophthalmologists at one Boston academic center found 17 NAION cases among 194 people with type 2 diabetes prescribed semaglutide, versus 6 among 516 people on other diabetes drugs (hazard ratio 4.28). The authors stressed that the study was observational and could not show cause and effect [4].
What is new in the semaglutide vision loss story?
The newest attention on semaglutide vision loss comes from lawsuits and drug safety reports, not from a new clinical trial. According to NPR's October 10 report [1]:
The lead court-appointed attorney represents 247 people who say they developed NAION.
The FDA's adverse event system has received more than 1,000 optic neuropathy reports linked to GLP-1 drugs since 2024, out of nearly 190,000 total reports. These reports are voluntary and unverified, so they cannot prove that a drug caused a problem.
The FDA has its own NAION risk study underway and has not asked for label changes.
The drug makers dispute the claims. Novo Nordisk calls the cases without merit, and Eli Lilly says it will defend against them.
Europe has moved further. In June 2025, the European Medicines Agency concluded that NAION is a "very rare" side effect of semaglutide and recommended adding it to the product information [2]. The World Health Organization followed with a medical product alert later that month [3].
How big is the NAION risk from semaglutide in the main studies?
Estimates of semaglutide's NAION risk differ because studies used different populations, comparison drugs and methods, and most relied on observational records that cannot prove cause.
Source | Who was studied | Main finding | What it means |
|---|---|---|---|
European Medicines Agency review (2025) [2] | Large studies in type 2 diabetes, plus trial data | About 2 times the risk vs non-users | About 1 extra case per 10,000 person-years |
Chrzanowski et al. (2026) [5] | Observational studies, type 2 diabetes | Hazard ratio 2.17 | About 1 extra case per 7,000 patients per year |
Nogueira et al. (2026) [8] | 15 studies, more than 1.5 million patients | Odds ratio 1.70 for GLP-1 drugs | Absolute risk 0.09%; number needed to harm about 2,700 |
Li et al. (2026) [6] | 20 randomized trials, 83,288 people | No significant increase | Odds ratio 1.50, 95% CI 0.49–4.63 |
Abdelaal et al. (2026) [9] | 6 observational studies, about 4.8 million people | No consistent overall increase | Low to very low certainty evidence |
The numbers differ because the studies used different populations, comparison drugs and methods. Almost all the evidence for harm comes from observational health records, which can show a link but cannot prove cause. That is one reason the FDA is still studying the semaglutide vision loss question [1].
Does semaglutide vision loss affect people taking it for weight loss?
The evidence here is weaker. In people with overweight or obesity, a 2026 analysis found a non-significant result (relative effect 1.68, 95% CI 0.72–3.91) [10]. A separate 2026 review found an adjusted hazard ratio of 0.47 (95% CI 0.19–1.13) for obesity or overweight, also not statistically significant [9]. That does not prove there is no risk of semaglutide vision loss in this group. It means the data so far do not show a clear signal.
Which GLP-1 drugs have been studied?
Most of the data involve semaglutide. A 2026 review of 1.46 million GLP-1 users estimated NAION at 85 cases per 100,000 GLP-1 users overall and 118 per 100,000 semaglutide users [11]. A class-wide analysis linked GLP-1 drugs as a group to a modest increase in risk (odds ratio 1.70) [8].
What should you do if you take semaglutide?
Because NAION is so rare, most people taking this medicine will never experience semaglutide vision loss [2]. Still, knowing what to watch for matters.
Do not stop on your own. The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have said the early research cannot show that the drug causes NAION, and they do not recommend stopping GLP-1s [1]. Talk with your prescriber first.
Know the warning sign. Contact a doctor without delay if you notice sudden vision loss or rapidly worsening eyesight [2][3]. Report blurred vision or other vision changes too [13].
Share your eye history. Tell your doctor if you have had NAION before or have been told your optic disc is at risk. A 2025 review advises caution in people with eye risk factors [12].
Keep your regular eye exams, especially if you have diabetes.
Weigh the full picture. Researchers note that the small NAION risk should be weighed against these medicines' well-established heart, kidney and survival benefits [8].
Frequently asked questions
Does semaglutide cause blindness?
No study has proven that semaglutide causes NAION. Observational studies show a link, mostly in type 2 diabetes, while randomized trials have not confirmed a clear increase [5][6]. When NAION does happen, it usually affects one eye and the vision loss is generally permanent [3].
How rare is NAION in people taking semaglutide?
Very rare. The European Medicines Agency estimates it may affect up to 1 in 10,000 people taking semaglutide, which is about one extra case per 10,000 person-years of treatment [2].
Should I stop taking semaglutide because of the vision risk?
Not without talking to your doctor. Eye specialists do not recommend stopping GLP-1s based on current evidence [1]. Regulators advise stopping semaglutide if NAION is confirmed [2][3].
What are the warning signs of NAION?
Sudden, painless loss of vision in one eye, or eyesight that gets rapidly worse [3]. If this happens, contact a doctor or go to urgent care right away [2].
Is the risk the same for weight loss and diabetes?
The signal is clearest in type 2 diabetes. Studies of people using semaglutide for weight loss have not shown a statistically significant increase so far [7][9][10].
Health information, not medical advice. This article explains published research for general education. It does not replace advice from your own doctor. Never start, stop or change a medicine without talking to a qualified health professional, and seek emergency care for sudden vision loss.
Sources
Noguchi Y. Ongoing lawsuits allege GLP-1s can cause serious harm. But we don't know how often. NPR. October 10, 2026. https://www.npr.org/2026/10/10/nx-s1-5996652/glp1-fda-naion-blind-lawsuit-ozempic
European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. European Medicines Agency. June 6, 2025 (updated June 13, 2025). https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
World Health Organization. The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION). World Health Organization. June 27, 2025. https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion
Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024;142(8):732-739. PMID 38958939. https://doi.org/10.1001/jamaophthalmol.2024.2296
Chrzanowski J, et al. Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies. PLoS Medicine. 2026;23(5):e1005064. PMID 42166479. https://doi.org/10.1371/journal.pmed.1005064
Li HY, et al. GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2026;49(3):526-535. PMID 41587563. https://doi.org/10.2337/dc25-1929
Liu Z, et al. Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis. Ophthalmology. 2026;133(5):589-598. PMID 41475544. https://doi.org/10.1016/j.ophtha.2025.12.022
Nogueira A, et al. Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis. Diabetes Care. 2026;49(5):724-729. PMID 41498755. https://doi.org/10.2337/dc25-1238
Abdelaal A, et al. Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis. Ophthalmology. 2026;133(6):799-810. PMID 41692115. https://doi.org/10.1016/j.ophtha.2026.02.013
Khani E, et al. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. Journal of Clinical Pharmacology. 2026;66(8):e70248. PMID 42612051. https://doi.org/10.1002/jcph.70248
Dhivagaran T, et al. Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis. Neurology. 2026;106(10):e214864. PMID 42060879. https://doi.org/10.1212/WNL.0000000000214864
Feldman-Billard S. What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes. Diabetes & Metabolism. 2025;51(4):101664. PMID 40383371. https://doi.org/10.1016/j.diabet.2025.101664
Mayo Clinic Staff. Semaglutide (subcutaneous route). Mayo Clinic. Updated October 1, 2026. https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730
Cobern J, Schulze E. What GLP-1 users should know about the potential risk of a rare type of vision loss. ABC News. September 21, 2026. https://abcnews.com/US/glp-1-users-potential-risk-rare-type-vision/story?id=136635318
About the author: Dr. Baraa Alnahhal, MD, is a medical doctor and the founder of Rinnit. Dr. Baraa Alnahhal reviews new medical research and translates it into clear, evidence-based health information for everyday readers.




Comments